Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170181 | 0.89 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL6169368 | 0.87 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL6170265 | 0.81 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL6171079 | 0.81 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL7484772 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL6169956 | 0.80 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL27554513 | 0.80 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL6171368 | 0.80 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL7479410 | 0.80 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL7507506 | 0.80 | PTGS2 (0.48) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | claimed |
| US-20050101653-A1 | Combination therapy for the treatment of migraine | SANDS GEORGE H (US) | 2005-05-12 | — | — | US | claimed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | claimed |
| US-6555540-B1 | Treatment of diabetic complications such as neuropathy, nephropathy, retinopathy and cardiomyopathy; for example zopolrestat and rofecoxib | PFIZER INC | 2003-04-29 | — | — | US | claimed |
| US-6476042-B1 | Combination therapy for the treatment of migraine | PFIZER INC. | 2002-11-05 | — | — | US | claimed |
| EP-1064965-A2 | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064966-A2 | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1051995-A2 | 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | claimed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | claimed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6555540-B1 | Treatment of diabetic complications such as neuropathy, nephropathy, retinopathy and cardiomyopathy; for example zopolrestat and rofecoxib | PFIZER INC | 2003-04-29 | — | — | US | disclosed |
| CN-1284064-A | 2,3-substituted indole compounds as cox-2 inhibitors | PFIZER PHARMA (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1064965-A2 | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101653-A1 | Combination therapy for the treatment of migraine | HTR1A, HTR2A, HTR1B | PTGS2 27/4885PTGS1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.